Immunoglobulin heavy chain translocations (t([email protected])) are suggested to portend a poor prognosis in chronic lymphocytic leukemia (CLL).
To determine the clinical significance of a t([email protected]) on CLL-specific cytogenetic abnormalities, we analyzed the outcomes of 142 CLL patients
referred for fluorescence in situ hybridization (FISH) analysis with our standard
FISH panel, which includes testing for a t([email protected]). Whereas patients with unfavorable (deletion 17p, deletion 11q) and intermediate
(trisomy 12, normal FISH) cytogenetics with concomitant t([email protected]) had similar median treatment-free survival (TFS) as those without a t([email protected]), patients with deletion 13q (del13q) and a t([email protected]) had significantly worse TFS than those without a t([email protected]): median TFS 4.7 versus 8.0 years, P = 0.03 (hazard ratio 4.21, 95% confidence interval 1.06–16.69 y, P = 0.04 in multivariate analysis after adjusting for age, sex, Rai stage, and white
blood cell count). The presence of a t([email protected]) further stratified patients with del13q into two prognostic entities, whereby outcomes
of those with coexistent del13q and a t([email protected]) were similar to outcomes of those with high risk cytogenetics. Knowledge of the
t([email protected]) status in CLL is therefore of clinical importance, as del13q patients with concomitant
t([email protected]) may not retain the previously expected favorable outcome.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Cancer GeneticsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Genomic aberrations and survival in chronic lymphocytic leukemia.N Engl J Med. 2000; 343: 1910-1916
- Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997.J Clin Oncol. 2007; 25: 799-804
- Importance of genetics in chronic lymphocytic leukemia.Blood reviews. 2011; 25: 131-137
- A comprehensive evaluation of the prognostic significance of 13q deletions in patients with B-chronic lymphocytic leukaemia.Br J Haematol. 2009; 148: 544-550
- Chromosome 14q32 translocations involving the immunoglobulin heavy chain locus in chronic lymphocytic leukaemia identify a disease subset with poor prognosis.Br J Haematol. 2008; 142: 529-537
- Toward a comprehensive prognostic scoring system in chronic lymphocytic leukemia based on a combination of genetic parameters.Genes Chromosomes Cancer. 2010; 49: 851-859
- Genetic and immunophenotypic profile of [email protected] rearrangement detected by fluorescence in situ hybridization in 149 cases of B-cell chronic lymphocytic leukemia.Cancer Genet Cytogenet. 2010; 196: 56-63
- Cytogenetic characterisation in Chinese patients with chronic lymphocytic leukemia: a prospective, multicenter study on 143 cases analysed with interphase fluorescence in situ hybridisation.Leuk Lymphoma. 2008; 49: 1887-1892
- Clinical and biologic implications of recurrent genomic aberrations in myeloma.Blood. 2003; 101: 4569-4575
- Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.Blood. 2008; 111: 5446-5456
- Oral fludarabine and rituximab as initial therapy for chronic lymphocytic leukemia or small lymphocytic lymphoma: population-based experience matches clinical trials.Leuk Lymphoma. 2012; 53: 77-82
British Columbia Cancer Agency. BC Cancer Agency cancer management guidelines: chronic leukemia. Available at: http://www.bccancer.bc.ca/HPI/CancerManagementGuidelines/Lymphoma/ChronicLeukemia.htm. Accessed on February 15, 2012.
- Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival.Haematologica. 2007; 92: 1242-1245
- Clonal evolution including 14q32/IGH translocations in chronic lymphocytic leukemia: analysis of clinicobiologic correlations in 105 patients.Leuk Lymphoma. 2011; 53: 83-88
- Interphase fluorescence in situ hybridization with an IGH probe is important in the evaluation of patients with a clinical diagnosis of chronic lymphocytic leukaemia.Br J Haematol. 2005; 130: 36-42
- Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia.Proc Natl Acad Sci USA. 2002; 99: 15524-15529
- The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia.Cancer Cell. 2010; 17: 28-40
- miR-15 and miR-16 induce apoptosis by targeting BCL2.Proc Natl Acad Sci USA. 2005; 102: 13944-13949
Article info
Publication history
Published online: August 31, 2012
Accepted:
May 23,
2012
Received in revised form:
May 22,
2012
Received:
March 18,
2012
Footnotes
T.L.G. and C.L.T. contributed equally to this study.
Identification
Copyright
© 2012 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
